Orano Med
Pierre Amadieu currently serves as the Coordinateur digitalisation industrielle at Orano Med, where responsibilities include overseeing the design and implementation of a future radionuclide production facility with a focus on Technologies and Information Systems & Industry 4.0. Previously, Pierre held positions at Orano from October 2008 to January 2022, including Chef de projet Innovation Mine digitale, where the emphasis was on developing innovation strategies for digital mining, and Ingénieur Procédés, which involved feasibility studies, international technical support, and economic evaluation. Pierre's academic background includes a Master's degree in Political Philosophy and Ethics from Université Paris-Sorbonne, an MBA from University of Paris I: Panthéon-Sorbonne, and an Engineering degree in Geology from Ecole Nationale Supérieure de Géologie.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.